Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of MultiHance vs Magnevist for contrast-enhanced MRA of peripheral arteries
2006-002274-22Phase 3Completed
- Sponsor
- Bracco Imaging
- Start
- Jul 2006
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gadobenate dimeglumine in peripheral artery occlusion (PAD) (2 arms), sponsored by Bracco Imaging. Primary endpoint: Global diagnostic preference. Started Jul 2006; status: completed.
02
Drugs
gadobenate dimeglumine
03
Conditions
peripheral artery occlusion (PAD)
Beyond the preview
Go deeper on 2006-002274-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002274-22.